No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

R2 Technologies Receives Series C Investment of $15 Mil

Editor: What To Know

  • Furthermore, RealSelf named Miami at the top of its list for the most aesthetic treatment providers and plastic surgeons per capita in 2018 and noted a strong correlation between tech hub hotspots and top medaesthetic markets, making it a prime marketplace for R2's in-office treatments.
  • In preparation for the unprecedented growth expected in the upcoming year, R2 is accelerating its manufacturing process to meet the current pent-up and future anticipated demands from the professional market.
  • According to a recent article, Florida has been noted as one of the hottest new business hubs with Fortune 500 businesses and tech firms expanding into the flourishing market, leading to notable financial growth.

R2 Technologies Inc. (“R2”) has received an additional round of $15 million in funding from its founding investor, Pansend Life Sciences, LLC, as a Series C equity investment which closed on July 20, 2021.

The investment established a post-money valuation of $150 million for R2. The funds will be used to expand the company’s corporate footprint and US commercial acceleration of Glacial Rx™, its first-to-market revolutionary CryoAesthetic™ treatment, FDA-cleared to remove benign lesions and temporarily reduce pain, swelling and inflammation. The investment will also fuel global growth and development of R2 Technologies’ upcoming innovations that are currently planned for future rollout.

 

“It is exciting to see our founding investor, Pansend, reinvest in the company. It is a testament to our business and the growth trajectory within the US and global markets,” says Tim Holt, R2’s Chief Executive Officer. “In fact, we will be one of the first global players in aesthetics who will have an East Coast office in Miami, Florida. This expansion will give us an unprecedented advantage especially as we expand globally and mobilize our growing sales force.”

In preparation for the unprecedented growth expected in the upcoming year, R2 is accelerating its manufacturing process to meet the current pent-up and future anticipated demands from the professional market. Additionally, the team will be ramping up marketing efforts to further drive education and awareness across both the consumer and professional channels.

R2 is doubling down on its presence in Silicon Valley with the expansion of its main office, while establishing a Miami-based satellite office. According to a recent article, Florida has been noted as one of the hottest new business hubs with Fortune 500 businesses and tech firms expanding into the flourishing market, leading to notable financial growth. Furthermore, RealSelf named Miami at the top of its list for the most aesthetic treatment providers and plastic surgeons per capita in 2018 and noted a strong correlation between tech hub hotspots and top medaesthetic markets, making it a prime marketplace for R2’s in-office treatments.

Developed by the pioneers of CoolSculpting and Fraxel, Glacial Rx was named among ‘2021 Launches Doctors are Buzzing About’ according to RealSelf, the leading and most trusted source to educate on cosmetic procedures. Most recently, R2 was named winner of the 2nd Annual Aesthetics Tech Summit LaunchPad SBDC, hosted by Octane, a company committed to making resources, capital and mentorship available to tech and medtech startups.

R2 is actively taking orders from aesthetic providers who want to offer the new Glacial Rx treatment in-office.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy